remoxy in vivo abuse resistance studies ping ji, phd senior clinical pharmacologist office of...
TRANSCRIPT
![Page 1: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/1.jpg)
RemoxyRemoxyIn VivoIn Vivo Abuse Resistance Abuse Resistance
StudiesStudies
RemoxyRemoxyIn VivoIn Vivo Abuse Resistance Abuse Resistance
StudiesStudies
Ping Ji, PhDSenior Clinical PharmacologistOffice of Clinical Pharmacology
Center of Drug Evaluation and ResearchFood and Drug Administration
Ping Ji, PhDSenior Clinical PharmacologistOffice of Clinical Pharmacology
Center of Drug Evaluation and ResearchFood and Drug Administration
![Page 2: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/2.jpg)
2
In VivoIn Vivo Abuse Resistance Abuse Resistance StudiesStudies
In VivoIn Vivo Abuse Resistance Abuse Resistance StudiesStudies
• Physical Disruption Study
• Mastication (chewing) Study
• Buccal Absorption Study
• Physical Disruption Study
• Mastication (chewing) Study
• Buccal Absorption Study
![Page 3: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/3.jpg)
3
Dose DumpingDose DumpingDose DumpingDose Dumping
• For opioids, Cmax is a critical pharmacokinetic parameter
• For the assessment of dose dumping, it is important to examine data from both individual and group mean basis
• For opioids, Cmax is a critical pharmacokinetic parameter
• For the assessment of dose dumping, it is important to examine data from both individual and group mean basis
![Page 4: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/4.jpg)
4
Cumulative Frequency AnalysisCumulative Frequency AnalysisCumulative Frequency AnalysisCumulative Frequency Analysis
• In a data set, the ‘more than’ cumulative frequency of a value x is the total number of observations that are more than or equal to x
• Frequency counts can be measured in terms of absolute numbers or relative numbers (e.g., proportions or percentages)
• In a data set, the ‘more than’ cumulative frequency of a value x is the total number of observations that are more than or equal to x
• Frequency counts can be measured in terms of absolute numbers or relative numbers (e.g., proportions or percentages)
0
20
40
60
80
100
0 0.2 0.4 0.6 0.8 1 1.2 1.4
X
Cu
mu
lati
ve
Re
lati
ve
Fre
qu
en
cy
(M
ore
Th
an
)
![Page 5: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/5.jpg)
5
Physical Disruption StudyPhysical Disruption Study
– Treatment A: Remoxy 40 mg capsule (whole)
– Treatment B: Remoxy 40 mg capsule (crushed, extracted with solvent)
– Treatment C: OxyContin 40 mg tablet (whole)
– Treatment D: OxyContin 40 mg tablet (crushed, extracted with solvent)
– Treatment E: Oxycodone oral solution 40 mg
– Treatment A: Remoxy 40 mg capsule (whole)
– Treatment B: Remoxy 40 mg capsule (crushed, extracted with solvent)
– Treatment C: OxyContin 40 mg tablet (whole)
– Treatment D: OxyContin 40 mg tablet (crushed, extracted with solvent)
– Treatment E: Oxycodone oral solution 40 mg
![Page 6: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/6.jpg)
6
Physical Disruption Study Physical Disruption Study Mean Oxycodone Plasma Concentration-Time Profiles
0
20
40
60
80
100
120
0 2 4 6 8 10 12
Time (h)
Oxy
cod
one
Con
c. (
ng/
mL
)
Oxycodone Oral SolutionOxyContin Crushed & ExtractedRemoxy Crushed & ExtractedOxyContin WholeRemoxy Whole
![Page 7: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/7.jpg)
7
Physical Disruption Study Physical Disruption Study
Remoxy OxyContin
Mean Oxycodone Plasma Concentration-Time Profiles
0
20
40
60
80
100
120
0 2 4 6 8 10 12
Time (h)O
xyco
done
Con
c. (
ng/m
L)
OxyContin Whole
OxyContin Crush & Extracted
0
20
40
60
80
100
120
0 2 4 6 8 10 12
Time (h)O
xyco
done
Con
c. (
ng/m
L)
OxyContin Whole
OxyContin Crush & Extracted
0
20
40
60
80
100
120
0 2 4 6 8 10 12
Time (h)
Oxy
codo
ne C
onc.
(ng
/mL
)
Remoxy Whole
Remoxy Crushed & Extracted
0
20
40
60
80
100
120
0 2 4 6 8 10 12
Time (h)
Oxy
codo
ne C
onc.
(ng
/mL
)
Remoxy Whole
Remoxy Crushed & Extracted
Treatment Ratio Cmax AUCRemoxy Crush /Remoxy Whole 2.07 (1.84-2.34) 1.07 (0.96-1.20)
OxyContin Crush/OxyContin Whole 2.12 (1.92-2.33) 1.01 (0.93-1.10)
Mean (90% CI)Statistical Comparison
![Page 8: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/8.jpg)
8
Physical Disruption Study Physical Disruption Study Mean Oxycodone Plasma Concentration-Time Profiles
Statistical Comparison
0
20
40
60
80
100
120
0 2 4 6 8 10 12
Time (h)
Oxy
cod
one
Con
c. (
ng/
mL
)
Oxycodone Oral SolutionOxyContin Crushed & ExtractedRemoxy Crushed & Extracted
Treatment Ratio Cmax AUCRemoxy Crush /Oxycodone Oral Solution 0.79 (0.74-0.84) 1.24 (1.19-1.30)
OxyContin Crush/Oxycodone Oral Solution 0.97 (0.89-1.06) 1.01 (0.96-1.07)
Mean (90% CI)
![Page 9: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/9.jpg)
9
Physical Disruption StudyPhysical Disruption StudyCumulative Frequency Plots
0
20
40
60
80
100
0 0.2 0.4 0.6 0.8 1 1.2 1.4
Cmax Ratio
Cu
mu
lati
ve
Re
lati
ve
Fre
qu
en
cy
(Mo
re T
ha
n)
Remoxy Crush/Oral solution Remoxy Whole/Oral solution
OxyContin Crush/Oral solution OxyContin Whole/Oral solution
![Page 10: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/10.jpg)
10
Physical Disruption Study Physical Disruption Study ConclusionConclusion
Physical Disruption Study Physical Disruption Study ConclusionConclusion
• The extended-release characteristics appeared to be compromised when Remoxy was subjected crushing and extraction with a solvent
• The extended-release characteristics appeared to be compromised when Remoxy was subjected crushing and extraction with a solvent
![Page 11: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/11.jpg)
11
Mastication StudyMastication Study
–Treatment A: Remoxy 40 mg capsule (whole)–Treatment B: Remoxy 40 mg capsule masticated rigorously and then swallowed–Treatment C: Oxycondone oral solution 40 mg
![Page 12: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/12.jpg)
12
Mean Oxycodone Plasma Concentration-Time Profiles
Mastication StudyMastication Study
Statistical Comparison
0
20
40
60
80
100
120
140
0 2 4 6 8 10 12
Time (h)
Oxy
codo
ne C
onc.
(ng
/mL
)
Remoxy MasticatedOxycodone Oral SolutionRemoxy Whole
Treatment Ratio Cmax AUCRemoxy Mastication/Remoxy Whole 2.20 (1.97-2.45) 1.10 (1.02-1.18)
Remoxy Mastication/Oxycodone Oral Solution 0.74 (0.70-0.79) 1.19 (1.15-1.22)
Mean (90% CI)
![Page 13: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/13.jpg)
13
Cumulative Frequency Plots Mastication StudyMastication Study
0
20
40
60
80
100
0 0.2 0.4 0.6 0.8 1 1.2 1.4Cmax Ratio
Cu
mu
lati
ve
Rel
ati
ve
Fre
qu
ency
(Mo
re T
han
)Mastication/Oral Solution
Whole/Oral Solution
Cmax Ratio Whole Mastication>0.8 2 35>0.9 1 15>1 1 10
Cumulative Relative Frequency (%)
![Page 14: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/14.jpg)
14
Mastication Study ConclusionMastication Study ConclusionMastication Study ConclusionMastication Study Conclusion
• The extended-release characteristics appeared to be compromised when Remoxy was subjected to mastication
• The extended-release characteristics appeared to be compromised when Remoxy was subjected to mastication
![Page 15: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/15.jpg)
15
Buccal Absorption StudyBuccal Absorption Study
–Treatment A: Remoxy 40 mg capsule (whole)–Treatment B: Remoxy 40 mg capsule held in the buccal cavity and then swallowed–Treatment C: Oxycodone oral solution 40 mg
![Page 16: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/16.jpg)
16
Buccal Absorption StudyBuccal Absorption StudyMean Oxycodone Plasma Concentration-Time Profiles
Statistical Comparison
0
20
40
60
80
100
120
0 2 4 6 8 10 12
Time (h)
Ox
yco
don
e C
on
c. (
ng
/mL
).Remoxy BuccalOxycodone Oral SolutionRemoxy Whole
Treatment Ratio Cmax AUCRemoxy Buccal/Remoxy Whole 1.83 (1.66-2.01) 1.11 (1.03-1.19)
Remoxy Buccal/Oxycodone Oral Solution 0.76 (0.71-0.81) 1.24 (1.20-1.29)
Mean (90% CI)
![Page 17: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/17.jpg)
17
Cumulative Frequency Plots
Buccal Absorption StudyBuccal Absorption Study
0
20
40
60
80
100
0 0.2 0.4 0.6 0.8 1 1.2 1.4
Cmax Ratio
Cu
mu
lati
ve R
ela
tive F
req
uen
cy
(Mo
re T
han
)Buccal/Oral Solution
Whole/Oral Solution
Cmax Ratio Whole Buccal>0.8 5 43>0.9 3 22>1 0 10
Cumulative Relative Frequency (%)
![Page 18: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/18.jpg)
18
Buccal Absorption Study Buccal Absorption Study ConclusionConclusion
Buccal Absorption Study Buccal Absorption Study ConclusionConclusion
• The extended-release characteristics appeared to be compromised when Remoxy was subjected to buccal absorption
• The extended-release characteristics appeared to be compromised when Remoxy was subjected to buccal absorption
![Page 19: Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research](https://reader033.vdocuments.us/reader033/viewer/2022061616/56649f1e5503460f94c36594/html5/thumbnails/19.jpg)
19
Overall SummaryOverall Summary
•The extended-release characteristics appeared to be compromised when Remoxy was subjected to crushing and extraction with ethanol, mastication, and buccal absorption